Escitalopram 20 mg

DRUG5 trials

Sponsors

H. Lundbeck A/S, Rigshospitalet, Denmark, Sadat City University, Odense University Hospital, Vigonvita Life Sciences

Conditions

HealthyMajor Depressive DisorderPolycystic Ovary Syndrome

Phase 1

The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients

WithdrawnNCT04410341

Sadat City UniversityMajor Depressive Disorder

Start: 2020-05-01End: 2024-12-01Updated: 2025-07-14

A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET

CompletedNCT06476509

Vigonvita Life SciencesMajor Depressive Disorder

Start: 2024-05-30End: 2025-05-23Updated: 2025-06-10

Phase 2

Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder

CompletedNCT00807248

H. Lundbeck A/SMajor Depressive Disorder

Start: 2008-11-30End: 2010-02-28Updated: 2012-12-17

Phase 4

Serotonergic Modulation of Cognition, Emotion and Brain Activation in Healthy Volunteers

CompletedNCT04239339

Rigshospitalet, DenmarkHealthy

Start: 2020-04-28End: 2022-10-30Updated: 2023-11-18

The Effect of Escitalopram in PCOS

CompletedNCT05840692

Odense University HospitalPolycystic Ovary Syndrome

Start: 2013-08-31End: 2017-10-31Updated: 2023-05-03

Related Papers

Functional brain responses to emotional faces after three to five weeks of intake of escitalopram in healthy individuals: a double-blind, placebo-controlled randomised study.

2024-02-074 citations

Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial

Molecular Psychiatry2023-10-0141 citations

Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study.

2023-01-2333 citations